Development of Resistance-Associated Mutations After Sotrovimab Administration in High-risk Individuals Infected With the SARS-CoV-2 Omicron Variant
Emma Birnie, Jason J. Biemond, Brent Appelman, Godelieve J. de Bree, Marcel Jonges, Matthijs R. A. Welkers, W. Joost Wiersinga
Abstract
This study investigates whether resistance-associated mutations develop after treatment with sotrovimab in high-risk patients infected with the SARS-CoV-2 Omicron variant.
Topics & Concepts
MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakVirologyMutationResistance (ecology)GeneticsGeneDiseaseInternal medicineBiologyEcologyInfectious disease (medical specialty)OutbreakSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesImmunotherapy and Immune Responses